Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls.

Sadzot B, Lemaire C, Maquet P, Salmon E, Plenevaux A, Degueldre C, Hermanne JP, Guillaume M, Cantineau R, Comar D, et al.

J Cereb Blood Flow Metab. 1995 Sep;15(5):787-97.

PMID:
7673371
2.

Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain.

Smith GS, Price JC, Lopresti BJ, Huang Y, Simpson N, Holt D, Mason NS, Meltzer CC, Sweet RA, Nichols T, Sashin D, Mathis CA.

Synapse. 1998 Dec;30(4):380-92.

PMID:
9826230
3.

In vivo binding of [18F]altanserin to rat brain 5HT2 receptors: a film and electronic autoradiographic study.

Biver F, Lotstra F, Monclus M, Dethy S, Damhaut P, Wikler D, Luxen A, Goldman S.

Nucl Med Biol. 1997 May;24(4):357-60.

PMID:
9257335
4.

Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography.

Biver F, Goldman S, Luxen A, Monclus M, Forestini M, Mendlewicz J, Lotstra F.

Eur J Nucl Med. 1994 Sep;21(9):937-46.

PMID:
7995287
5.

Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats.

Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L.

J Nucl Med. 1991 Dec;32(12):2266-72.

6.

Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent.

Tan PZ, Baldwin RM, Van Dyck CH, Al-Tikriti M, Roth B, Khan N, Charney DS, Innis RB.

Nucl Med Biol. 1999 Aug;26(6):601-8.

PMID:
10587097
7.

PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin.

van Dyck CH, Tan PZ, Baldwin RM, Amici LA, Garg PK, Ng CK, Soufer R, Charney DS, Innis RB.

J Nucl Med. 2000 Feb;41(2):234-41.

8.

Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans.

Price JC, Lopresti BJ, Meltzer CC, Smith GS, Mason NS, Huang Y, Holt DP, Gunn RN, Mathis CA.

Synapse. 2001 Jul;41(1):11-21.

PMID:
11354009
9.

Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging.

Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, de Groot T, Schiepers C, Verbruggen A, Mortelmans L.

Psychiatry Res. 1996 Nov 25;68(1):11-22.

PMID:
9027929
10.
11.

Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach.

Pinborg LH, Adams KH, Svarer C, Holm S, Hasselbalch SG, Haugbøl S, Madsen J, Knudsen GM.

J Cereb Blood Flow Metab. 2003 Aug;23(8):985-96.

PMID:
12902843
12.

Influence of synaptic serotonin level on [18F]altanserin binding to 5HT2 receptors in man.

Larisch R, Klimke A, Hamacher K, Henning U, Estalji S, Hohlfeld T, Vosberg H, Tosch M, Gaebel W, Coenen HH, Müller-Gärtner HW.

Behav Brain Res. 2003 Feb 17;139(1-2):21-9.

PMID:
12642173
13.

Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm.

van Dyck CH, Soares JC, Tan PZ, Staley JK, Baldwin RM, Amici LA, Fu X, Garg PK, Seibyl JP, Charney DS, Innis RB.

Nucl Med Biol. 2000 Nov;27(8):715-22.

PMID:
11150702
14.

Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography.

Quednow BB, Treyer V, Hasler F, Dörig N, Wyss MT, Burger C, Rentsch KM, Westera G, Schubiger PA, Buck A, Vollenweider FX.

Neuroimage. 2012 Feb 15;59(4):3922-32. doi: 10.1016/j.neuroimage.2011.09.045.

PMID:
21996132
15.

Analyses of [(18)F] altanserin bolus injection PET data. I: consideration of radiolabeled metabolites in baboons.

Price JC, Lopresti BJ, Mason NS, Holt DP, Huang Y, Mathis CA.

Synapse. 2001 Jul;41(1):1-10.

PMID:
11354008
16.

Direct comparison of [(18) F]MH.MZ and [(18) F] altanserin for 5-HT2A receptor imaging with PET.

Hansen HD, Ettrup A, Herth MM, Dyssegaard A, Ratner C, Gillings N, Knudsen GM.

Synapse. 2013 Jun;67(6):328-37. doi: 10.1002/syn.21643.

PMID:
23390031
17.

Distribution of 5HT2A receptors in the human brain: comparison of data in vivo and post mortem.

Forutan F, Estalji S, Beu M, Nikolaus S, Hamacher K, Coenen HH, Vosberg H, Müller-Gärtner HW, Larisch R.

Nuklearmedizin. 2002;41(4):197-201.

PMID:
12224404
18.

Comparison of [(18)F]altanserin and [(18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies.

Staley JK, Van Dyck CH, Tan PZ, Al Tikriti M, Ramsby Q, Klump H, Ng C, Garg P, Soufer R, Baldwin RM, Innis RB.

Nucl Med Biol. 2001 Apr;28(3):271-9.

PMID:
11323237
19.

Disturbance of serotonin 5HT2 receptors in remitted patients suffering from hereditary depressive disorder.

Larisch R, Klimke A, Mayoral F, Hamacher K, Herzog HR, Vosberg H, Tosch M, Gaebel W, Rivas F, Coenen HH, Müller-Gärtner HW.

Nuklearmedizin. 2001 Aug;40(4):129-34.

PMID:
11556203
20.

Validation and quantification of [18F]altanserin binding in the rat brain using blood input and reference tissue modeling.

Riss PJ, Hong YT, Williamson D, Caprioli D, Sitnikov S, Ferrari V, Sawiak SJ, Baron JC, Dalley JW, Fryer TD, Aigbirhio FI.

J Cereb Blood Flow Metab. 2011 Dec;31(12):2334-42. doi: 10.1038/jcbfm.2011.94.

Items per page

Supplemental Content

Support Center